Compare Incyte Corporation (INCY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marqeta Inc — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Marqeta Inc trades at $15.61 (market cap $1.62B). The key difference: Incyte Corporation is far larger — about 15.1× Marqeta Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MQ | |
|---|---|---|
Market Cap | $24.54B | $1.62B |
Sector | Health | Technology |
52-Week High | $129.93 | $26.00 |
52-Week Low | $81.61 | $15.04 |
Enterprise Value | $20.04B | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
MQ trades at $15.59, down slightly by 0.06%. The stock exhibits a bearish technical signal with strong selling pressure on moving averages. Fundamentally, the company shows improving revenue trends, with 2026 revenue projected at $677 million and a return to positive net income. Recent partnerships with Google and Riskified highlight strategic growth initiatives in digital payments and fraud prevention.
MQ's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but high valuation ratios and past earnings volatility present risks. Analyst consensus is a 'Hold' with a $19 price target, suggesting moderate upside potential from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
